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1. Introduction 
TRK-820 (nalfurafine hydrochloride) is a selective opioid  receptor agonist (Fig. 1) that was 
launched as an antipruritic for hemodialysis patients in Japan in 2009. In general, clinically 
used opioids, such as morphine, exhibit potent antinociceptive effects and simultaneous 
severe adverse effects, including drug dependence, derived from the opioid  receptor. To 
develop analgesics without drug dependence,  receptor agonists are investigated. 
However, conventional  agonists, arylacetamide derivatives, showed aversive effects like 
psychotomimetic effects, and have not yet been used clinically. On the other hand, the novel 
 agonist TRK-820 has no dependent or aversive properties. TRK-820, which has a structure 
different from arylacetamides, was first developed as an analgesic for postoperative pain, 
but the indication was changed to pruritus (Nakao & Mochizuki, 2009; Nagase & Fujii, 
2011). The rational drug design and synthesis of the compound have been reported (Kawai 
et al., 2008; Nagase et al., 1998; Nagase & Fujii, 2011); therefore, in this chapter, we will focus 
on its pharmacological properties. 
 
Fig. 1. Structure of nalfurafine hydrochloride (TRK-820) 
2. Opioid receptor type selectivity (In vitro) 
The binding affinities of TRK-820 were evaluated using various tritiated ligands and opioid 
receptors derived from various species (Table 1). The  selectivity over the  receptor (Ki 
ratio /) tended to be higher than over the  receptor (Ki ratio /). Binding affinities for 
the L-type Ca2+ channel and 45 receptors, except the opioid receptors, were examined 
(Nakao & Mochizuki, 2009). Among the tested receptors, TRK-820 showed the strongest 
affinity for the muscarine M1 receptor, but its Ki value was 1,700 nmol/L and approximately 
7,000 times higher than that of the  receptor. A comparison of the binding properties of 
TRK-820 and a conventional  agonist, U-69,593, was noteworthy. In a competitive binding 
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Ki (nM) Ki ratio
References     
53 1200 3.5 15 343 Seki et al., 1999 
5.2 161 0.075 69 2147 Wang, Y et al., 2005 
0.71 49.9 0.36 2.0 139 Vanderah et al., 2008 
2.21 484 0.244 9.1 1984 Nakao & Mochizuki, 2009 
0.582 96.5 0.225 2.6 429 Nagase et al., 2010 
Table 1. Binding affinities (Ki values) and selectivities (Ki ratios) of TRK-820 for the opioid 
receptors. Seki et al. used [3H]bremazocine and the recombinant rat opioid receptors. Wang, Y 
et al. used [3H]diprenorphine and recombinant rat , recombinant mouse, and recombinant 
human receptors. Vanderah et al. used [3H]DAMDO, [3H]pCl-DPDPE, and [3H]U-69,593 for 
the recombinant human , , and  receptors, respectively. Nakao et al. used 
[3H]diprenorphine and the recombinant human receptors. Nagase et al. used [3H]DAMDO, 
[3H]NTI, and [3H]U-69,593 for the μ, δ, and κ receptors, respectively. Guinea pig forebrain or 
guinea pig cerebellum was used to assay the  and  receptor or  receptor, respectively. 
 
Assay 
Selectivity 
References  
MVD 980 NC Kawai et al., 2008 
GPI 78.6 – Kawai et al., 2008 
cAMP (Sato et al.) 55 >6,667 Seki et al., 1999 
cAMP (Nakao et al.) 203 2,610 Nakao & Mochizuki, 2009 
[35S]GTPS 128 11,560 Wang, Y et al., 2005 
Table 2. Selectivities of TRK-820 in various functional assays. Selectivity in MVD and GPI 
assays was obtained by Ke ratios. The selectivity for the  receptor over the  receptor in the 
MVD assay was not calculated (NC) due to a lack of agonist activity for the  receptor. The 
selectivity for the  receptor over the  receptor in the GPI assay was not obtained because GPI 
preparation contained only the  and  receptors. Seki et al. and Nakao et al. used the 
recombinant rat and human receptors in their assays, respectively. In the [35S]GTPS binding 
assay, recombinant rat , recombinant mouse, or recombinant human  receptors were used. 
assay using [3H]TRK-820, TRK-820 completely replaced [3H]TRK-820 binding, whereas U-
69,593 did not replace it completely, with roughly 20% of [3H]TRK-820 binding remaining. 
Moreover, Scatchard analysis of [3H]TRK-820 and [3H]U-69,593 binding using guinea pig 
cerebellum showed that TRK-820 had stronger binding affinity than U-69,593 (Kd values: 
0.46±0.03 nM for [3H]TRK-820, 1.17±0.14 nM for [3H]U-69,593) and that the Bmax value for 
[3H]TRK-820 (284±43.3 fmol/mg protein) was significantly higher than the value for [3H]U-
69,593 (83.7±7.86 fmol/mg protein). Even in the presence of  agonist DAMDO (100 nM) 
and  agonist DPDPE (200 nM), the Kd and Bmax values for [3H]TRK-820 did not change (Kd = 
0.51±0.03 nM, Bmax = 265±27.2 fmol/mg protein) (Endoh et al., 2000). These results suggest 
that TRK-820 was selective ligand for the  receptor and that its binding property for the  
receptor was different from that of the conventional  agonist U-69,593. Many binding 
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assays are carried out using [3H]U-69,593 because it is commercially available. However, the 
binding property of TRK-820 is difficult to be definitively evaluated because [3H]TRK-820 is 
not available now. 
TRK-820 was selective for the  receptor, but the selectivity over the  receptor was 
apparently not as high in the binding assays. Contrarily TRK-820 showed more selectivities 
for the  receptor in functional assays: MVD (mouse vas deference) and GPI (guinea pig 
ileum) assay (Nagase et al., 1998), cAPM assay (Nakao & Mochizuki, 2009; Seki et al., 1999), 
and [35S]GTPS binding assay (Wang, Y et al., 2005) (Table 2). The results of the cAMP assay 
(IC50 () = 8.3±1.4 nM, Imax () = 69±3%, IC50 () > 1,000 nM, Imax () not determined, IC50 () 
= 0.15±0.07 nM, Imax () = 81±3% by Seki et al.; IC50 () = 1.66±0.09 nM, Imax () = 53.2±1.3%, 
IC50 () = 21.3±1.0 nM, Imax () = 77.9±1.6%, IC50 () = 0.00816±0.00138 nM, Imax () = 
91.3±0.5% by Nakao et al.) indicated that TRK-820 was a selective and potent full agonist for 
the  receptor and partial agonist for the  and  receptors. The potency for the  receptor 
was very low (Nakao & Mochizuki, 2009; Seki et al., 1999). The [35S]GTPS binding assay 
provided similar results (EC50 () = 3.2±1.3 nM, Emax () = 54±7%, EC50 () = 289±60 nM, Emax 
() = 51±6%, EC50 () = 0.025±0.003 nM, Emax () = 93±5%) (Wang, Y et al., 2005). Mizoguchi 
et al. exhibited partial agonist activity of TRK-820 for the  receptor in both in vitro and in 
vivo assays (Mizoguchi et al., 2003). TRK-820 concentration- or dose-dependently attenuated 
[35S]GTPS binding by DAMGO or antinociception induced by intracerebroventricular 
(i.c.v.) administration of DAMGO. On the other hand, the effects of morphine alone or a 
mixture with TRK-820 were investigated using a mouse acetic acid-induced writhing test or 
warm water (50 ºC) tail-withdrawal assay in rhesus monkeys (Ko & Husbands, 2009; 
Nagase, 2010). Isobologram analysis of the results showed that additive or synergetic effects 
for TRK-820 in combination with morphine in the antinociceptive effect were observed, 
indicating that TRK-820 had no  antagonist activity, at least no antagonism against 
analgesic activity induced by morphine. Why the effects of TRK-820 against DAMGO 
differed from those against morphine is not clear. 
 
Fig. 2. Isobologram for the mixture of TRK-820- and morphine-induced antinociception in 
the mouse acetic acid-induced writhing test. Reprinted with permission from Nagase, 2010. 
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3. Analgesic effects 
TRK-820 showed potent analgesic effects in some species (rodents and primates) with 
various stimuli: chemical, thermal, or mechanical stimuli and inflammatory, diabetic, 
herpetic, and postherpetic pain models. The antinociceptive effects of TRK-820 are 
summarized in Tables 3-7. Subcutaneous (s.c.) administration of TRK-820 produced dose-
dependent and profound antinociceptive effects in the low temperature hot plate, tail flick, 
tail pressure, and tail pinch tests. However, TRK-820 was not as effective in high 
temperature hot plate tests (Table 3) (Endoh et al., 1999). 
In a rat paw pressure test, TRK-820 given s.c. or intramuscularly (i.m.) induced dose-
dependent and sufficient analgesic effects, which were suppressed by pre-treatment with 
selective  antagonist nor-BNI (Table 3). The antinociceptive effect by TRK-820 (ED50 = 0.064 
mg/kg, s.c.) was 170, 2, 20, and 78-fold more potent than U-50,488H, CI-977, morphine, and 
pentazocine, respectively (ED50 values : 11.0, 0.15, 1.3, and 5.0 mg/kg) (Endoh et al., 2000). 
 
Compound 
High 
temperture hot 
plate (55 ºC) 
Low 
temperature hot 
plate (51 ºC) 
Tail flick
Tail 
pressure 
Tail 
pinch 
TRK-820 32.0 % at 0.2 0.129 0.062 0.009 0.035 
U-50,488H 63.8 % at 20 8.71 5.18 1.0 11.5 
ICI-199,441 n.t. 0.065 0.042 0.024 0.051 
U-69,593 n.t. 1.33 n.t. 0.48 2.8 
CI-977 n.t. n.t. n.t. n.t. n.t. 
PD-117302 n.t. n.t. n.t. n.t. n.t. 
Pentazocine 44.6 % at 40 52.2 n.t. n.t. n.t. 
Morphine 3.65 5.30 5.26 1.5 12.2 
 
Compound Paw pressure Formalin test 
Acetic acid-induced 
writhing test 
TRK-820 0.064 0.0096 0.0033 
U-50,488H 11.0 n.t. 1.16 
ICI-199,441 0.074 0.0095 0.0071 
CI-977 0.15 n.t. 0.0069 
PD-117302 n.t. n.t. 1.22 
Pentazocine 5.0 n.t. n.t. 
Morphine 1.3 0.975 0.58 
Table 3. ED50 values (mg/kg, s.c.) of the antinociceptive effects of some opioid agonists in 
various tests. U-50,488H, U-69,593, ICI-199,441, CI-977, and PD-117302 are conventional  
agonists. n.t. : not tested. Hot plate, tail flick, tail pressure, tail pinch, and acetic acid-induced 
writhing tests were performed in mice (Endoh et al., 1999). Paw pressure and formalin tests 
were performed in rats (Endoh et al., 2000). 
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In the formalin test, s.c. TRK-820 given 15 min prior to the formalin injection markedly 
inhibited the second phase of the nociceptive response induced by formalin in a dose-
dependent manner. However, the analgesic effect of TRK-820 was low for the first phase of the 
formalin response. Similarly, a conventional  agonist, ICI-199,441, also markedly inhibited the 
second phase. On the other hand, a  agonist, morphine inhibited both phases in a dose-
dependent manner. The antinociceptive potencies of TRK-820 and ICI-199,441 were almost 
equivalent (Table 3) (Endoh et al., 2000). A potent and dose-dependent antinociceptive effect of 
TRK-820 (i.m.) was also observed in cynomolgus monkeys. The analgesic effect of TRK-820 
was 295 and 492-fold more potent than that of morphine in the 50 ºC and 55 ºC hot water tests, 
respectively, and 40 and 1000-fold more potent than that of U-50,488H and pentazocine in the 
50 ºC hot water test, respectively (Table 4) (Endoh et al., 2001). 
Furthermore, the antinociceptive effects of TRK-820 administered s.c. and perorally (p.o.) 
were compared. The dose-dependent antinociception of TRK-820 (ED50 = 0.0033 mg/kg, s.c. 
and 0.032 mg/kg, p.o.) in the acetic acid-induced writhing test were inhibited by pre-
treatment with nor-BNI. The antinociceptive effects induced by s.c. or p.o. administration of 
TRK-820 were 351 and 796-fold more potent than those induced by U-50,488H, respectively, 
and 175 and 187-fold more potent than those induced by morphine, respectively. Because 
the ED50 p.o./s.c. ratio for TRK-820 was the least among the tested compounds, TRK-820 
was expected to be the most effective agent when administered p.o. (Table 5) (Endoh et al., 
1999). Intravenous administration of TRK-820 was also reported to be effective in the same 
test (Vanderh et al., 2008). 
The effect of repeated administration of some  agonists and morphine on antinociceptive 
tolerance was examined by the acetic acid-induced writhing test in mice. After five 
 
Compound 50 ºC hot water 55 ºC hot water 
TRK-820 0.0078 0.012 
Morphine 2.3 5.9 
U-50,488H 0.31 n.t. 
Pentazocine > 10 n.t. 
Table 4. ED50 values (mg/kg, i.m.) of antinociceptive effects induced by some opioid 
agonists in the hot water tail withdrawal test in cynomolgus monkeys. n.t. : not tested. 
 
Compound s.c. p.o. ED50 p.o./s.c. ratio 
TRK-820 0.0033 0.032 9.7 
U-50,488H 1.16 25.5 22.0 
CI-977 0.0069 > 1.0 > 145 
ICI-199441 0.0071 0.3 42.3 
PD-117302 1.22 33.0 27.0 
Morphine 0.58 6.01 10.4 
Table 5. ED50 values (mg/kg, s.c. or p.o.) for antinociceptive effects induced by some opioid 
agonists in the acetic acid-induced writhing test in mice. 
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administrations of TRK-820 (0.1-0.8 mg/kg, s.c.), U-50,488H (10-80 mg/kg, s.c.), ICI-199,441 
(0.025-0.2 mg/kg, s.c.), or morphine (1.25-10 mg/kg, s.c.) over three days, the development 
of tolerance to the antinociception induced by each compound at a fixed dose was assessed 
and tolerance ED50 was calculated. Comparing the ratio of tolerance ED50 to acute 
antinociceptive ED50 of each compound, TRK-820 was found to develop the least tolerance 
to antinociception (Table 6) (Suzuki et al., 2004).  
An analgesic effect of TRK-820 (i.m.) was also examined using rats with arthritis induced by 
adjuvant. TRK-820 dose-dependently produced potent and equivalent antinociceptive 
activity in both arthritic and normal rats in the paw pressure test. Similar results were 
obtained when morphine was injected i.m. However, the analgesic effect of a conventional  
agonist, ICI-199,441, in the arthritic rats was less potent than in normal rats (Table 7) (Endoh 
et al., 2000). 
 
Compound Tolerance ED50 
Acute 
antinociceptive ED50 
Ratio of tolerance 
ED50/acute 
antinociceptive ED50 
TRK-820 0.54 0.0033 163.6 
U-50,488H 30.7 1.16 26.5 
ICI-199,441 0.078 0.0071 11.0 
Morphine 5.72 0.58 9.9 
Table 6. ED50 values (mg/kg, s.c.) for tolerance and antinociceptive effects induced by some 
opioid agonists in the acetic acid-induced writhing test. 
 
Compound Normal rat Arthritic rat 
ED50 ratio of arthritic 
rat/ normal rat 
TRK-820 0.055 0.095 1.7 
ICI-199,441 0.047 0.24 5.1 
Morphine 1.1 1.1 1.0 
Table 7. ED50 values (mg/kg, i.m.) for antinociceptive effects induced by some opioid 
agonists in the paw pressure test in normal and arthritic rats. 
In streptozotocin-induced diabetic mice, the antinociceptive effects induced by several  
agonists, including TRK-820, were compared in the tail flick test. Intrathecal (i.t.) and i.c.v. 
administration of TRK-820 produced dose-dependent antinociceptive effects in both diabetic 
and non-diabetic mice. However, antinociception induced by TRK-820 administered i.t. or 
i.c.v. in diabetic mice were less potent than antinociception in non-diabetic mice. However, 
the antinociceptive effects of CI-977 administered i.t., but not i.c.v., in diabetic mice were 
less potent than those in non-diabetic mice. On the other hand, the antinociceptive effects of 
ICI-199,441 and R-84760 injected i.c.v., but not i.t., in diabetic mice were less potent than 
those in non-diabetic mice. These results indicate that the antinociceptive effects of  
agonists in diabetic mice are altered in a region-specific manner in the central nervous 
system and by chemotypes of  agonists (Ohsawa et al., 2005). 
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In acute herpetic and postherpetic pain models induced by herpes simplex virus type-1 
infection in mice, TRK-820 dose-dependently and remarkably inhibited the allodynia and 
hyperalgesia stimulated by von Frey filaments (Takasaki et al., 2004, 2006). The effects of 
TRK-820, but not morphine, were not significantly different between herpetic and 
postherpetic pain (Takasaki et al., 2006). TRK-820 (0.1 mg/kg, s.c.) almost completely 
relieved both allodynia and hyperalgesia in herpetic pain, whereas a high dose of morphine 
(20 mg/kg, s.c.) did not produce complete inhibition. However, TRK-820 (0.01-0.1 mg/kg, 
s.c.) did not affect the spontaneous locomotor activity of normal mice (Takasaki et al., 2004). 
Moreover, repeated administration of TRK-820 (0.1 mg/kg, p.o., twice daily) produced 
constant inhibition of allodynia and hyperalgesia in herpetic pain. The effects of the fourth 
administration with TRK-820 were not significantly different from those of the first 
administration. On the other hand, the effects of morphine rapidly decreased after repeated 
administration (20 mg/kg, p.o., twice daily). The effects of the third and fourth 
administration of morphine were significantly weaker than those of the first administration. 
Pre-treatment with morphine (20 mg/kg, p.o., three times) did not affect the antinociceptive 
effect of TRK-820 (0.1 mg/kg, p.o.), whereas the effect of morphine (20 mg/kg, p.o.) was 
significantly reduced (Takasaki et al., 2006). These results indicate that TRK-820 is effective 
on both herpetic and postherpetic pain in mice. In addition, the analgesic dose of TRK-820 
did not develop acute tolerance and induced cross-tolerance to morphine in herpetic pain. 
4. Antipruritic effects 
4.1 Preclinical studies 
The p.o. administration of TRK-820 dose-dependently inhibited scratching behavior induced 
by histamine in mice, which is one of the representative pruritogenic substances, without 
obvious suppression of spontaneous locomotor activity. The antiscratching activity of TRK-
820 with ED50 7.3 g/kg was antagonized by nor-BNI (Togashi et al., 2002). TRK-820 was 
effective in scratching induced by the other pruritogenic substances: substance P (Togashi et 
al., 2002; Umeuchi et al., 2003; Utsumi et al., 2004), chloroquine (Inan & Cowan, 2004), 
compound 48/80 (Wang, Y et al., 2005), agmatin (Inan & Cowan, 2006a), and 5'-GNTI (Inan 
et al., 2009a, 2011) (Table 8). 5'-GNTI-induced scratching was suppressed by both pre-
treatment and post-treatment with TRK-820. Tolerance did not develop to the antiscratching 
effect of TRK-820 in the subchronic study (Inan et al., 2009a). 
 
Pruritogenic 
substance 
Antipruritic effect References 
Histamine ED50 = 7.3 g/kg, p.o. Togashi et al., 2002 
Substance P ED50 = 19.6 g/kg, p.o. Togashi et al., 2002 
Chloroquine 
TRK-820 (120 g/kg, p.o.) suppressed the 
scratching almost completely
Inan & Cowan, 2004 
Compound 48/80 ED50 = 6.64 g/kg, s.c. Wang, Y et al., 2005 
Agmatin TRK-820 (0.02 mg/kg, s.c.) was effective Inan & Cowan, 2006a 
5'-GNTI 
TRK-820 (20 g/kg, s.c.) suppressed the 
scratching almost completely
Inan et al., 2009a 
Table 8. The antipruritic effects of TRK-820 against itching behaviors induced by various 
pruritogenic substances. 
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Fig. 3. Effects of TRK-820 on scratching induced by i.t. administration of morphine in rhesus 
monkeys. TRK-820 (0 (□), 0.1 (▲), 0.3 (●), and 1 (▼) g/kg, i.m.) was given 45 min after the 
administration of morphine (0.03 mg, i.t.). * p < 0.05 between vehicle and time points 1 and 
2.5 h. Reprinted with permission from Ko & Husbands, 2009. 
 
Fig. 4. Effects of TRK-820 on scratching behaviors observed in NC/Nag mice maintained in 
a conventional environment. ##p < 0.01, Welch test. **p < 0.01 compared to NC/Nag mice not 
treated with TRK-820, parametric Dunnett multiple comparison test. Reprinted with 
permission from Nakao et al., 2008. 
Although epidural or i.t. administration of a  agonist like morphine is an important 
method for pain management, an itching sensation is the most common side effect 
(Ballantyne et al., 1988; Cousins & Mather, 1984). The effect of TRK-820 on morphine-
induced scratching in mice or primates was also evaluated (Ko & Husbands, 2009; Utsumi et 
al., 2004; Wakasa et al., 2004). Intramuscular administration of TRK-820 (0.3–1 g/kg) dose-
dependently attenuated scratching induced by morphine (i.t.) in rhesus monkeys without 
affecting antinociception by morphine (Fig. 3) (Ko & Husbands, 2009). 
TRK-820 reportedly exhibited antipruritic effects on spontaneous scratching behavior in 
aged MRL/lpr mice (a possible model for pruritus in autoimmune disease) (Umeuchi et al., 
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2005) or NC/Nag mice maintained in a conventional environment (an animal model for 
atopic dermatitis) (Nakao et al., 2008), and scratching behavior secondary to cholestasis 
induced chronic ethynylestradiol injections in rats (Inan & Cowan, 2006b). Interestingly, 
TRK-820 was effective in scratching behaviors observed in conventional NC/Nag mice, 
which were considered a model of atopic dermatitis (Fig. 4). 
4.2 Clinical studies 
Wikström et al. (2005) and Kumagai et al. (2010) reported the results of randomized, double-
blind, placebo-controlled clinical studies in which TRK-820 was administered to patients 
undergoing hemodialysis intravenously or orally (Fig. 5). In these studies, TRK-820 
exhibited significant antipruritic effects without severe adverse drug reactions. These 
outcomes suggest that TRK-820 can be considered a safe agent. 
TRK-820 is prescribed in Japan as an antipruritic for hemodialysis. Very recently, Kumagai 
et al. reported that TRK-820 has been prescribed for approximately 18,000 hemodialysis 
patients and effective in 70 to 80% (Kumagai et al., 2011). 
 
Fig. 5. Changes in VAS (visual analogue scale) values from the pre-observation period. All 
symbols show the mean values of VAS changes. *p < 0.025 compared to placebo, one-sided 
ANCOVA. Reprinted from Nagase & Fujii, 2011 with permission from Springer 
Science+Business Media. The VAS test consisted of a 100-mm horizontal line without scale 
markings. The patients were asked to mark the intensity of itching on the scale, with the 
right end of the line (100 mm) indicating the strongest possible itching and the left end (0 
mm) indicating no itching. 
5. Effects of TRK-820 on drug dependence 
5.1 Effects of TRK-820 in the conditioned place preference (CPP) test 
The agonists have a rewarding effect, which accounts for the abuse of morphine by humans. 
In animal models, the rewarding effects of  agonists have been evaluated by the conditioned 
place preference (CPP) and self-administration paradigms (Di Chiara & North, 1992). In 
contrast to μ agonists, conventional κ agonists such as U-50,488H and U-69,593 generally lack 
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a rewarding effect (Dykstra et al., 1997). However in the CPP test, animals avoid an 
environment associated with the administration of the  agonists, indicating that these drugs 
have aversive effects (Barr et al., 1994; Funada et al., 1993). In contrast to conventional  
agonists, such as U-50,488H, TRK-820 (3.0-30 g/kg, s.c.) did not induce significant place 
aversion in mice at doses producing significant antinociception (Fig. 6) (Nagase, 2010). 
Notably, TRK-820 exhibited neither preferential nor aversive properties. Recently, the peroral 
administration of TRK-820 (5.0 g/day) was reported to show no signs of psychological or 
physical dependence in an open-labeled clinical trial for one year (Nagase & Fujii, 2011). 
 
Fig. 6. The effect of TRK-820 in the CPP test. Reprinted with permission from Nagase, 2010. 
5.2 The effects of TRK-820 on morphine and cocaine-induced rewarding effects 
The mechanism of  agonist-induced rewarding effects is outlined below. The activation of 
the  receptor on -aminobutyric acid-containing interneurons is likely to disinhibit 
ventrotegmental area dopaminergic neurons, thereby increasing dopamine release in their 
terminal areas, including the nucleus accumbens (N.Acc). On the other hand, the activation of 
the receptor decreases dopamine release in the N.Acc (Di Chiara & Imperato, 1988; Spanagel 
et al., 1992). Therefore,  agonists may be useful for treating morphine dependence. Indeed, 
the pretreatment with U-50,488H attenuated the morphine-induced place preference in mice 
(Funada et al., 1993). TRK-820 also significantly suppressed the place preference produced by 
morphine, and the effect of TRK-820 was antagonized by pre-treatment with nor-BNI (3.0 
mg/kg, s.c.) in mice (Tsuji et al., 2001). In addition, TRK-820 was effective in reducing the 
rewarding effect produced by cocaine. TRK-820 (20 and 40 g/kg, i.p.), at doses producing no 
aversive or sedative effects, suppressed the rewarding effect of cocaine (4.0 mg/kg, i.p.) in rats 
(Mori et al., 2002). U-50,488H and U-69,593 exhibited similar effects as TRK-820 (Shippenberg 
et al., 1996; Suzuki et al., 1992). Drug discrimination procedures provide relevant information 
about neuropharmacological mechanisms underlying the subjective effects of abused drugs, 
including cocaine, methamphetamine, and opioids, in animals. Therefore, the procedures are 
potentially useful for identifying candidate therapeutics for the management of drug abuse 
(Schuster & Johanson, 1988). Pre-treatment with TRK-820 (10 and 20 g/kg, s.c.) significantly 
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shifted the dose-response curve for cocaine (10 mg/kg, i.p.) to the right without changing the 
response rate. This attenuating effect of TRK-820 was completely reversed by pre-treatment 
with nor-BNI (10 mg/kg, s.c.) (Mori et al., 2002). 
5.3 Effects of TRK-820 on the morphine withdrawal response 
In humans, withdrawal from the chronic administration of opioids such as morphine results 
in characteristic behaviors, including anxiety, nausea, insomnia, hot and cold flashes, muscle 
aches, perspiration, and diarrhea. Such symptoms would pose clinical problems in patients 
receiving long-term treatment with opioids for pain relief. Rodents that are physically 
dependent on morphine elicit characteristic signs (jumping, wet dog shakes, rearing, 
diarrhea, ptosis, and forepaw tremor) when administrated naloxone. The withdrawal signs 
precipitated by naloxone are used as an index of the physical dependence on morphine. The 
effects of  agonists TRK-820 and U-50,488H on the development of physical dependence on 
morphine were reported. Co-injection of TRK-820 (0.003-0.03 mg/kg, s.c.) during chronic 
morphine treatment dose-dependently suppressed naloxone-precipitated body weight loss, 
and the other withdrawal signs in morphine-dependent mice treated with TRK-820 (0.03 
mg/kg, s.c.) were significantly fewer than those in untreated mice. In contrast to TRK-820, 
co-injection of U-50,488H (1.0-10 mg/kg, s.c.) did not inhibit naloxone-precipitated body 
weight loss and other withdrawal signs (Tsuji et al., 2000). 
5.4 The effect of TRK-820 on the nicotine-withdrawal response 
Nicotine withdrawal produces characteristic syndromes, including irritability, anxiety, 
depression, and craving for nicotine. Pre-treatment with TRK-820 (10 and 30 μg/kg, s.c.) or 
U-50,488H (0.01-1.0 mg/kg, s.c.) has been reported to decrease dose-dependently 
mecamylamine-precipitated nicotine-withdrawal aversion in nicotine-dependent rats (Ise et 
al., 2002). 
6. Comparison of pharmacological properties between TRK-820 and 
conventional  agonists 
We described in the previous sections some pharmacological properties of TRK-820 that are 
different from conventional  agonists, arylacetamides such as U-50,488H and U-69,593: 
binding properties (section 2) and exhibition of no preferential and no aversive effect in the 
CPP paradigm (section 5). As described below, drug discrimination procedures indicate 
conclusive difference between TRK-820 and arylacetamides. 
6.1 Discriminative tests 
Drug discrimination procedures have shown that the properties of TRK-820 differ from 
those of conventional  agonists, such as U-50,488H. In the cross-substitution tests using 
rats, U-50,488H (1.0-3.0 mg/kg) substituted for the discriminative stimulus effects of TRK-
820 (40 g/kg, i.p.), whereas TRK-820 (10-76 g/kg) did not completely substitute for those 
of U-50,488H (3.0 mg/kg, i.p.). E-2078 (0.3-3.0 mg/kg), but not R-84760 (0.01-0.3 mg/kg), 
substituted for the discriminative stimulus effects of both TRK-820 and U-50,488H. KT-90 
(0.03-3.0 mg/kg), CI-977 (1-30 mg/kg), or ICI-199441 (3.0-56 mg/kg) substituted for the 
discriminative stimulus effects of U-50,488H, but not for those of TRK-820 (Mori et al., 2004). 
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In this study, cross-substitution between the discriminative effects of U-50,488H and TRK-
820 was not observed. The  agonists tested in this study, except E-2078, tended to substitute 
for the discriminative stimulus effects of U-50,488H rather than those of TRK-820. These 
results suggest that U-50,488H and TRK-820 have differential properties. Furthermore, non-
competitive NMDA antagonists phencyclidine (PCP, 0.5-2.0 mg/kg) and MK-801 (10-80 
g/kg) dose-dependently generalized to the discriminative stimulus effects of U-50,488H 
(3.0 mg/kg, i.p.) in the cross-substitution tests. On the other hand, PCP and MK-801 at doses 
that generalized to the discriminative stimulus effects of U-50,488H did not generalize to 
those of TRK-820 (40 g/kg, i.p.) (Mori et al., 2006). The outcomes clearly indicate different 
properties between TRK-820 and U-50,488H. 
7. Other pharmacological effects 
7.1 The effect of TRK-820 on a rat model of schizophrenia 
The effects of TRK-820 on hyperlocomotion and stereotyped behaviors (head-weaving, 
sniffing, and turning) induced by PCP were evaluated. These behaviors are thought to 
resemble the schizophrenia-like effects in humans. TRK-820 (10–100 g/kg, s.c.) dose-
dependently inhibited PCP (10 mg/kg, i.p.)-induced hyperlocomotion, and this effect was 
antagonized with nor-BNI (20 mg/kg, s.c.). PCP-induced stereotyped behaviors were also 
inhibited by treatment with TRK-820 in a dose-dependent manner. These findings that TRK-
820 potentially ameliorates abnormal behaviors induced by PCP suggest its therapeutic 
potential against the symptoms of schizophrenia (Yoshikawa et al., 2009). 
7.2 The effect of TRK-820 on dyskinesia symptoms in a parkinsonian rat model 
The effects of TRK-820 on rotational behavior were investigated in unilateral 6-
hydroxydopamine (6-OHDA)-treated rats (hemi-parkinsonian rats), and on dyskinesia 
produced by administering L-DOPA to hemi-parkinsonian rats for 3 weeks (dyskinesia 
rats). TRK-820 significantly ameliorated abnormal behavior in hemi-parkinsonian rats at 30 
g/kg (s.c.), and L-DOPA induced dyskinesia at 10 and 30 g/kg (s.c.). This effect was 
antagonized by pretreatment with nor-BNI (20 mg/kg, s.c.). Additionally, co-administration 
of TRK-820 (3 and 10 μg/kg, s.c.) with L-DOPA for 3 weeks suppressed the development of 
L-DOPA-induced dyskinesia. TRK-820 may be a suitable drug for the treatment of 
parkinsonian patients with dyskinesia symptoms (Ikeda et al., 2009). 
7.3 The diuretic effect of TRK-820 in rats 
Diuresis is a well-recognized effect of conventional  agonists in animals and humans. A 
diuretic effect of TRK-820 in rats has also been reported. TRK-820 (0.005-0.02 mg/kg, s.c.) 
dose-dependently induced a diuretic effect without developing tolerance, and this effect 
was inhibited by selective  antagonist 5’-GNTI (Inan et al., 2009b). 
7.4 The effects of TRK-820 on endothelial cell differentiation and development of 
vasculature 
The roles of the opioid  system in vascular development were investigated (Yamamizu et 
al., 2011). U-50,488H and TRK-820 significantly inhibited endothelial cell differentiation and 
vascular formation through the inhibition of cAMP/PKA signaling. 
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8. Conclusion 
TRK-820 was a selective  agonist. However, its pharmacological properties were different 
from those of conventional arylacetamide  agonists, including U-50,488H. A noteworthy 
feature of TRK-820 was that it showed no preferential or aversive properties, whereas U-
50,488H produced aversion. This disparity of properties between TRK-820 and 
arylacetamide  agonists was reported to stem from the difference in  receptor subtypes 
each compound interacted with: arylacetamide  agonists would interact with 1 receptor 
subtype, whereas TRK-820 may interact with another  receptor subtype (perhaps 3) 
(Endoh et al., 1999; 2000; 2001; Tsuji et al., 2000a; 2000b). Although opioid receptors have 
been classified historically into three types (, , and  types) and further divided into 
several subtypes from the pharmacological viewpoint (Dhawan et al., 1996), only the three 
major types have been cloned (Satoh & Minami, 1995). Much evidence has been compiled 
indicating that various receptors, including opioid receptors, exist as homo- or hetero 
dimers of the receptors (George et al., 2000, 2002; Gomes et al., 2000, 2004; Devi, 2001; Levac 
et al., 2002; Wang, D et al., 2005), and receptor dimerization has been invoked to explain the 
discrepancy between widely varied pharmacologies and the identification of only three 
opioid receptor types. Therefore, the disparity of properties between TRK-820 and 
arylacetamide  agonists may stem from the difference in receptor dimers each compound 
interacts with. Both TRK-820 and arylacetamide  agonists are expected to be useful tools 
for the investigation of receptor dimerization and/or  receptor subtype. As mentioned in 
section 2, a binding assay using [3H]TRK-820 and [3H]U-69,593 is thought to be a facile and 
useful method for achieving that purpose. However, [3H]TRK-820 is not currently available. 
In addition to antipruritic and antinociceptive effects, TRK-820 exhibited various 
pharmacological effects, such as the treatment of the symptoms of schizophrenia or 
dyskinesia symptoms of parkisonian patients, or remedy for drug addiction. Moreover, 
TRK-820 has been already launched in Japan. TRK-820 is expected not only to be developed 
with the other indication, such as symptoms of schizophrenia or parkinson's disease, but 
also to be utilized to investigate pharmacology via the  receptor. 
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